AMAM Stock Overview
Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Ambrx Biopharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$28.00 |
| 52 Week High | US$28.15 |
| 52 Week Low | US$6.55 |
| Beta | 0 |
| 1 Month Change | 0.79% |
| 3 Month Change | 121.34% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 104.83% |
Recent News & Updates
Shareholder Returns
| AMAM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.2% | 0.4% | 1.0% |
| 1Y | n/a | 0.9% | 21.9% |
Return vs Industry: Insufficient data to determine how AMAM performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how AMAM performed against the US Market.
Price Volatility
| AMAM volatility | |
|---|---|
| AMAM Average Weekly Movement | 29.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AMAM's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine AMAM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 87 | Dan O'Connor | ambrx.com |
Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology.
Ambrx Biopharma Inc. Fundamentals Summary
| AMAM fundamental statistics | |
|---|---|
| Market cap | US$1.77b |
| Earnings (TTM) | -US$67.06m |
| Revenue (TTM) | US$4.09m |
433.4x
P/S Ratio-26.5x
P/E RatioIs AMAM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMAM income statement (TTM) | |
|---|---|
| Revenue | US$4.09m |
| Cost of Revenue | US$0 |
| Gross Profit | US$4.09m |
| Other Expenses | US$71.15m |
| Earnings | -US$67.06m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.06 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,638.31% |
| Debt/Equity Ratio | 0% |
How did AMAM perform over the long term?
See historical performance and comparison